Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
3,585 JPY +1.41% Intraday chart for Kissei Pharmaceutical Co., Ltd. +4.82% +16.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI
Kissei Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 8, 2023, has closed with 1,909,900 shares, representing 4.18% for ¥5,999.99 million. CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024 CI
Kissei Pharmaceutical Repurchases 251 Million Yen Worth of Shares in December 2023 MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching MT
Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis CI
Japanese Shares Close Lower on Tuesday After Key Economic Data MT
Kissei Pharmaceutical's Fiscal H1 Attributable Profit Surges as Net Sales Gains MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Kissei Pharmaceutical Co., Ltd. Announces Second Quarter-End Dividend for the Year Ending March 31, 2024, Payable on December 4, 2023 and Provided Dividend Guidance for the Year Ending March 31, 2024 CI
Jefferies Downgrades Kissei Pharmaceutical to Hold From Buy, Adjusts Price Target to 3,400 Yen From 3,300 Yen MT
Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023 CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 CI
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024 CI
Kissei Pharmaceutical Withdraws Marketing Approval Application for Rovatirelin MT
Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan CI
Kissei Pharmaceutical Co., Ltd. Introduces Iktos AI Drug Discovery System CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023. CI
The Hachijuni Bank, Ltd. completed the acquisition of the remaining 98.33% stake in The Naganobank, Ltd. from The Master Trust Bank of Japan, Ltd. (Trust Account), Custody Bank of Japan, Ltd. (Trust Account), The Tochigi Bank, Ltd., Kissei Pharmaceutical Co., Ltd.,Sompo Japan Insurance Inc. and others. CI
Kissei Pharmaceutical's Full-Year Profit Falls 18.5% MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024 CI
Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 23, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 CI
Chart Kissei Pharmaceutical Co., Ltd.
More charts
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3,585 JPY
Average target price
3,833 JPY
Spread / Average Target
+6.93%
Consensus
  1. Stock Market
  2. Equities
  3. 4547 Stock
  4. News Kissei Pharmaceutical Co., Ltd.
  5. Kissei and Maruishi Debut Injection for Dialysis-Related Itching